Ординатура / Офтальмология / Английские материалы / Anti-VEGF_Bandello, Parodi, Augustin_2010

Acute multifocal posterior placoid pigment epitheliopathy (AMPPPE), features and management 89, 90

Age-related macular degeneration (AMD) epidemiology 21, 22 neovascularization features 1, 2 vascular endothelial growth factor

therapeutic targeting ANCHOR Study 29, 30 bevacizumab 24–26 FOCUS Study 28, 29 MARINA Study 29 pegaptanib 23, 24 PIER Study 28 PrONTO study 30 ranibizumab 26–30 rationale 22

AMD, see Age-related macular degeneration AMPPPE, see Acute multifocal posterior

placoid pigment epitheliopathy ANCHOR Study 29, 30 Angiopoietins

angiogenic activity of angiopoietin-2 12 angiostasis 2

mural cell recruitment and maturation 14 Angiostatin, uveal melanoma metastasis

studies 128

BCR, see Birdshot chorioretinopathy Behçet’s disease, ocular features and

management 87, 88 Best’s dystrophy, features and

management 107, 108 Bevacizumab

age-related macular degeneration studies 24–26

Behçet’s disease management 88

Best’s dystrophy management 107, 108 birdshot chorioretinopathy management

89

choroidal neovascularization management 75–79

cystoid macular edema management 91 diabetic retinopathy management 117 diabetic retinopathy studies 45–49 multifocal choroiditis management 86 neovascular glaucoma management 128 ocular histoplasmosis syndrome

management 87

pattern dystrophy management 108 persistent placoid maculopathy

management 91 pseudoxanthoma elasticum

management 99–101 pterygium management 137

radiation retinopathy management 128 retinal vein occlusion management 65, 67,

119

retinitis pigmentosa management 109 rubeosis iridis management 136

Sorsby fundus dystrophy management 109 Bevasiranib, diabetic retinopathy studies 49 Birdshot chorioretinopathy (BCR), features

and management 88, 89

Cadherins, VE cadherins and angiostasis 2, 12 Choroidal neovascularization (CNV), see also

specific diseases

inflammatory chorioretinal disease association 84

natural history 74 pathologic myopia 73 treatment

juxtafoveal myopic disease 78–82

Choroidal neovascularization (CNV) subfoveal myopic disease 75–78 vascular endothelial growth factor

inhibitors 75–79

CNV, see Choroidal neovascularization Collagen, angiostasis 2

Corneal neovascularization, features and management 133–135

Corticosteroids

corneal neovascularization management 134

multifocal choroiditis management 85, 86 retinal vein occlusion management 64,

119

Diabetic retinopathy (DR) epidemiology 39

macular edema association and vascular endothelial growth factor therapeutic targeting 112, 113, 115–118

vascular endothelial growth factor therapeutic targeting

bevacizumab 45–49 bevasiranib 49 pegaptanib 43, 44 ranibizumab 41–43 rapamycin 50 rationale 40

VEGF Trap Eye 49 DR, see Diabetic retinopathy

EC, see Endothelial cell Elastin, angiostasis 2 Endothelial cell (EC)

cell-cell interactions 12 differentiation and angiogenesis 5 proliferation 11, 12

tip and stalk cell regulation 11

FGF, see Fibroblast growth factor Fibrin, angiostasis 2

Fibroblast growth factor (FGF), angiogenesis role 11

FOCUS Study 28, 29

Fundus flavimaculatus, features and management 109

Hemodilution, retinal vein occlusion management 61

Irvine-Gass syndrome 114

Lumen, formation in angiogenesis 13

Macular edema, see also specific diseases cystoid macular edema features and

management 91, 111

diabetic retinopathy association 112, 113, 115–118

inflammatory chorioretinal disease association 84, 85, 114, 115, 120

pathogenesis 111, 112

retinal vein occlusion association 113, 114, 118–120

vascular endothelial growth factor therapeutic targeting 115–120

MARINA Study 29

Matrix metalloproteinases (MMPs), angiogenesis role 11

MC, see Multifocal choroiditis Melanoma, see Uveal melanoma

MEWDS, see Multiple evanescent white dot syndrome

MMPs, see Matrix metalloproteinases Multifocal choroiditis (MC), features and

management 85, 86

Multiple evanescent white dot syndrome (MEWDS), features and management 88

Mural cell, recruitment and maturation 14

Neovascular glaucoma (NVG)

radiation induction and management 128 rubeosis iridis 135, 136

NVG, see Neovascular glaucoma

OCT, see Optical coherence tomography Ocular histoplasmosis syndrome (OHS),

features and management 87

OHS, see Ocular histoplasmosis syndrome Optical coherence tomography (OCT),

vascular endothelial growth factor therapeutic targeting findings age-related macular degeneration 31–34 pseudoxanthoma elasticum 102, 103

Pattern dystrophy, features and management 108

PDGF, see Platelet-derived growth factor PDT, see Photodynamic therapy

PEDF, see Pigment epithelium-derived factor Pegaptanib

age-related macular degeneration studies 23, 24

diabetic retinopathy studies 43, 44, 117 Pentoxifylline, retinal vein occlusion

management 61, 62

Persistent placoid maculopathy (PPM), features and management 90, 91

Photocoagulation

choroidal neovascularization management 78–82

retinal vein occlusion management 62, 63 rubeosis iridis management 135

Photodynamic therapy (PDT), choroidal neovascularization management 78–82

Picropodophyllin, uveal melanoma metastasis management 128

PIER Study 28

PIGF, see Placenta growth factor

Pigment epithelium-derived factor (PEDF) angiostasis 2, 3, 8

uveal melanoma metastasis studies 128 Placenta growth factor (PlGF), angiogenesis

role 10

Platelet-derived growth factor (PDGF), mural cell recruitment and maturation 14

PPM, see Persistent placoid maculopathy Preretinal angiogenesis, pathology 17 PrONTO study 30

Pseudoxanthoma elasticum (PXE) clinical features 97

genetics 97, 98 history of study 96

ocular signs and symptoms 98, 99 treatment 99–104

Pterygium, features and management 136, 137 PXE, see Pseudoxanthoma elasticum

Radiation retinopathy local treatment 128 overview 127

Ranibizumab

acute multifocal posterior placoid pigment epitheliopathy management 90

age-related macular degeneration studies 26–30

Best’s dystrophy management 107, 108 choroidal neovascularization

management 75

diabetic retinopathy management 117 diabetic retinopathy studies 41–43 fundus flavimaculatus management 109 multiple evanescent white dot syndrome

management 88

neovascular glaucoma management 128 pseudoxanthoma elasticum

management 99–101 pterygium management 137

retinal vein occlusion management 65, 66

Rapamycin, diabetic retinopathy studies 50 Retina

angioblasts 16 angiogenesis 16

development of vasculature 15, 16 patterning 17

unique features of circulation 15 vasculature 14, 15

Retinal vein occlusion (RVO)

macular edema association and vascular endothelial growth factor therapeutic targeting 113, 114, 118–120

pathogenesis 55–57 prophylaxis 67 risk factors 55–58

symptoms and course

branch retinal vein occlusion 59, 60 central retinal vein occlusion 57, 59 hemicentral retinal vein occlusion

59 treatment

acute interventions 61 corticosteroids 64 photocoagulation 62, 63 rheological therapy 61, 62 surgery 63, 64 thrombolysis 62

vascular endothelial growth factor inhibitors 64–67

types 54

Retinitis pigmentosa, features and management 108, 109

Retinoblastoma angiogenesis

induction 124 inflammation 127 overview 123, 124 regulation 125, 126

epidemiology 123 treatment prospects 129, 130

Rubeosis iridis, features and management 135, 136

RVO, see Retinal vein occlusion SC, see Serpiginous choroiditis

Serpiginous choroiditis (SC), features and management 90

Sorsby fundus dystrophy, features and management 109

Subretinal angiogenesis, pathology 18

TGF-β, see Transforming growth factor-β Thalidomide, uveal melanoma metastasis

management 128 Thrombospondin, angiostasis 2

Tissue plasminogen activator (tPA), retinal vein occlusion management 62

tPA, see Tissue plasminogen activator Transforming growth factor-β (TGF-β),

angiogenesis role 12 Triamcinolone

diabetic retinopathy management 115 radiation retinopathy management 128

Troxerutin, retinal vein occlusion management 61, 62

Uveal melanoma angiogenesis

induction 124 inflammation 127

overview 123, 124 regulation 125, 126

metastasis and angiogenesis 128, 129 radiation retinopathy

local treatment 128 overview 127

treatment prospects 129, 130 vascular mimicry 125

Vascular endothelial growth factor (VEGF) angiogenesis role 3, 6

blood vessel guidance 13

endothelial cell proliferation induction 11, 12

intravitreal trap 30, 31, 49

therapeutic targeting, see Bevacizumab, Bevasiranib, Pegaptanib, Ranibizumab, Rapamycin

tip and stalk cell regulation 11 types and receptors 8, 10

VEGF, see Vascular endothelial growth factor

Wound healing, homology with pathological ocular angiogenesis 18